Biomarkers in Cancer

The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy

Submit a Paper

Biomarkers in Cancer 2016:Suppl. 2 39-45


Published on 23 May 2016

DOI: 10.4137/BIC.S31798

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Biomarkers in Cancer


With the improvement of cancer therapy, survival related to malignancy has improved, but the prevalence of long-term cardiotoxicity has also increased. Cancer therapies with known cardiac toxicity include anthracyclines, biologic agents (trastuzumab), and multikinase inhibitors (sunitinib). The most frequent presentation of cardiac toxicity is dilated cardiomyopathy associated with poorest prognosis. Monitoring of cardiac toxicity is commonly performed by assessment of left ventricular (LV) ejection fraction, which requires a significant amount of myocardial damage to allow detection of cardiac toxicity. Accordingly, this creates the impetus to search for more sensitive and reproducible biomarkers of cardiac toxicity after cancer therapy. Different biomarkers have been proposed to that end, the most studied ones included troponin release resulting from cardiomyocyte damage and natriuretic peptides reflecting elevation in LV filling pressure and wall stress. Increase in the levels of troponin and natriuretic peptides have been correlated with cumulative dose of anthracycline and the degree of LV dysfunction. Troponin is recognized as a highly efficient predictor of early and chronic cardiac toxicity, but there remains some debate regarding the clinical usefulness of the measurement of natriuretic peptides because of divergent results. Preliminary data are available for other biomarkers targeting inflammation, endothelial dysfunction, myocardial ischemia, and neuregulin-1. The purpose of this article is to review the available data to determine the role of biomarkers in decreasing the risk of cardiac toxicity after cancer therapy.




BibTex citation   (BIBDESK, LATEX)


What Your Colleagues Say About Biomarkers in Cancer
Biomarkers in Cancer, was again a pleasant experience.  We received helpful suggestions from the reviewers and an efficient, very professional editing processing process afterwards. Excellent team-work!  We hope for the same quantity of reads/citations as for our previous publication in Clinical Medicine Insights: Oncology.
Dr Cornelis F.M. Sier (Leiden University Medical Center, Netherlands)
More Testimonials

Quick Links

New article and journal news notification services